CD274 and cancer: Although the applications of anti-PD1/PD-L1 antibodies in clinical revolutionized cancer treatment, small-molecule inhibiting of PD-L1 expression as a potential therapeutic approach sill offer certain benefits compared to anti-PD-L1 antibody, which is sometimes trigger immune-related adverse events (irAEs) due to nonspecific immunological activation[13].